Compugen Ltd
CGEN1.530USD
+0.010+0.68%
Market hours （ET）Quotes delayed by 15 min
143.14MMarket Cap
LossP/E TTM
More Details of Compugen Ltd Company
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Compugen Ltd Info
Ticker SymbolCGEN
Company nameCompugen Ltd
IPO dateAug 01, 2000
CEOOphir (Eran)
Number of employees74
Security typeOrdinary Share
Fiscal year-endAug 01
AddressAzrieli Center
CityHOLON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code5885849
Phone97237658585
Websitehttps://cgen.com/
Ticker SymbolCGEN
IPO dateAug 01, 2000
CEOOphir (Eran)
Company Executives of Compugen Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
56.12K
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
--
--
Mr. Eran Ophir
Mr. Eran Ophir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
--
--
Ms. Yvonne Naughton, Ph.D.
Ms. Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Head of Investor Relations and Corporate Communications
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
56.12K
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Ms. Michelle Mahler
Ms. Michelle Mahler
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
22.86M
82.06%
Europe
5.00M
17.94%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SilverArc Capital Management, LLC
3.54%
Bristol Myers Squibb
1.97%
Renaissance Technologies LLC
1.50%
Nomura Investment Management Business Trust
1.09%
Taylor Frigon Capital Management LLC
1.03%
Other
90.87%
Shareholders
Shareholders
Proportion
SilverArc Capital Management, LLC
3.54%
Bristol Myers Squibb
1.97%
Renaissance Technologies LLC
1.50%
Nomura Investment Management Business Trust
1.09%
Taylor Frigon Capital Management LLC
1.03%
Other
90.87%
Shareholder Types
Shareholders
Proportion
Hedge Fund
6.18%
Investment Advisor
5.35%
Corporation
1.97%
Investment Advisor/Hedge Fund
1.48%
Research Firm
0.58%
Individual Investor
0.06%
Family Office
0.04%
Bank and Trust
0.02%
Other
84.32%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
119
12.73M
17.35%
--
2025Q3
125
12.73M
18.34%
-2.70M
2025Q2
126
16.23M
19.87%
+39.65K
2025Q1
133
16.24M
16.64%
+1.34M
2024Q4
138
13.37M
17.09%
+210.15K
2024Q3
152
13.17M
21.08%
-305.68K
2024Q2
162
13.42M
29.55%
-531.69K
2024Q1
196
13.93M
29.95%
-12.89M
2023Q4
205
11.91M
32.36%
-1.05M
2023Q3
223
12.99M
32.04%
+1.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SilverArc Capital Management, LLC
3.03M
3.24%
+138.45K
+4.78%
Jun 30, 2025
Bristol Myers Squibb
1.84M
1.97%
-2.92M
-61.32%
Dec 31, 2024
Renaissance Technologies LLC
1.33M
1.42%
-68.17K
-4.89%
Jun 30, 2025
Nomura Investment Management Business Trust
1.02M
1.09%
--
--
Jun 30, 2025
Taylor Frigon Capital Management LLC
994.65K
1.06%
-54.65K
-5.21%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
843.03K
0.9%
+40.53K
+5.05%
Jun 30, 2025
Northern Trust Global Investments Limited
889.72K
0.95%
+8.48K
+0.96%
Jun 30, 2025
Two Sigma Investments, LP
342.43K
0.37%
+2.45K
+0.72%
Jun 30, 2025
State Street Investment Management (US)
351.18K
0.38%
+7.05K
+2.05%
Jun 30, 2025
Atom Investors LP
329.52K
0.35%
+143.00
+0.04%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
SPDR S&P International Small Cap ETF
0.01%
Invesco NASDAQ Future Gen 200 ETF
0%
ARK Israel Innovative Technology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
SPDR S&P International Small Cap ETF
Proportion0.01%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
ARK Israel Innovative Technology ETF
Proportion0%
SPDR Portfolio Developed World ex-US ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Compugen Ltd?
The top five shareholders of Compugen Ltd are:
SilverArc Capital Management, LLC holds 3.03M shares, accounting for 3.24% of the total shares.
Bristol Myers Squibb holds 1.84M shares, accounting for 1.97% of the total shares.
Renaissance Technologies LLC holds 1.33M shares, accounting for 1.42% of the total shares.
Nomura Investment Management Business Trust holds 1.02M shares, accounting for 1.09% of the total shares.
Taylor Frigon Capital Management LLC holds 994.65K shares, accounting for 1.06% of the total shares.
SilverArc Capital Management, LLC holds 3.03M shares, accounting for 3.24% of the total shares.
Bristol Myers Squibb holds 1.84M shares, accounting for 1.97% of the total shares.
Renaissance Technologies LLC holds 1.33M shares, accounting for 1.42% of the total shares.
Nomura Investment Management Business Trust holds 1.02M shares, accounting for 1.09% of the total shares.
Taylor Frigon Capital Management LLC holds 994.65K shares, accounting for 1.06% of the total shares.
What are the top three shareholder types of Compugen Ltd?
The top three shareholder types of Compugen Ltd are:
SilverArc Capital Management, LLC
Bristol Myers Squibb
Renaissance Technologies LLC
SilverArc Capital Management, LLC
Bristol Myers Squibb
Renaissance Technologies LLC
How many institutions hold shares of Compugen Ltd (CGEN)?
As of 2025Q4, 119 institutions hold shares of Compugen Ltd, with a combined market value of approximately 12.73M, accounting for 17.35% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.98%.
What is the biggest source of revenue for Compugen Ltd?
In FY2024, the -- business generated the highest revenue for Compugen Ltd, amounting to -- and accounting for --% of total revenue.
